Diagnostic performance of apparent diffusion coefficient values in differentiating benign from malignant lesions in prostate PI-RADS v2.1 category 1 "nodules in nodule".
[OBJECTIVES] To explore the associations between the apparent diffusion coefficient (ADC) values of prostate PI-RADS v2.1 category 1 "nodules in nodule" and their pathological characteristics.
- p-value p < 0.001
- p-value p < 0.05
APA
Sun M, Li F, et al. (2025). Diagnostic performance of apparent diffusion coefficient values in differentiating benign from malignant lesions in prostate PI-RADS v2.1 category 1 "nodules in nodule".. Abdominal radiology (New York), 50(11), 5292-5304. https://doi.org/10.1007/s00261-025-04930-y
MLA
Sun M, et al.. "Diagnostic performance of apparent diffusion coefficient values in differentiating benign from malignant lesions in prostate PI-RADS v2.1 category 1 "nodules in nodule".." Abdominal radiology (New York), vol. 50, no. 11, 2025, pp. 5292-5304.
PMID
40293519
Abstract
[OBJECTIVES] To explore the associations between the apparent diffusion coefficient (ADC) values of prostate PI-RADS v2.1 category 1 "nodules in nodule" and their pathological characteristics.
[METHODS] We retrospectively analyzed the prostate images from 226 male patients who underwent biopsy following MRI from January 2019 to December 2024. Two radiologists evaluated the PI-RADS v2.1 categories of identified nodules, measured the ADC values of the prostate nodules in a double-blind manner, and analyzed the associations between these values and the pathological characteristics of the nodules via independent sample t tests or Mann-Whitney U test.
[RESULTS] The ADC values of PI-RADS v2.1 category 1 "nodules in nodule" pathologically confirmed as clinically significant prostate cancer (csPCa) were lower than those of benign prostate hyperplasia (BPH) ((unit in ×10 mm/s)TZ: 0.739 ± 0.15 versus 0.984 ± 0.24; PZ: 0.719 ± 0.17 versus 1.036 ± 0.21, p < 0.001). The AUCs were 0.799 (TZ) with a cutoff of 0.835 × 10mm/s, and 0.873(PZ) with a cutoff of 0.795 × 10mm/s, respectively. The total prostate-specific antigen (tPSA), free/t PSA, PSA density (PSAD), and prostate gland volume (PGV) differed significantly between patients with PI-RADS v2.1 "nodules in nodule" that were pathologically confirmed as csPCa and patients with BPH (all p < 0.05).
[CONCLUSION] In patients with PI-RADS v2.1 category 1 "nodules in nodule", when the ADC values are less than 0.835 × 10mm/s in the TZ, the PI-RADS v2.1 score of the nodule can be upgraded to 3.
[METHODS] We retrospectively analyzed the prostate images from 226 male patients who underwent biopsy following MRI from January 2019 to December 2024. Two radiologists evaluated the PI-RADS v2.1 categories of identified nodules, measured the ADC values of the prostate nodules in a double-blind manner, and analyzed the associations between these values and the pathological characteristics of the nodules via independent sample t tests or Mann-Whitney U test.
[RESULTS] The ADC values of PI-RADS v2.1 category 1 "nodules in nodule" pathologically confirmed as clinically significant prostate cancer (csPCa) were lower than those of benign prostate hyperplasia (BPH) ((unit in ×10 mm/s)TZ: 0.739 ± 0.15 versus 0.984 ± 0.24; PZ: 0.719 ± 0.17 versus 1.036 ± 0.21, p < 0.001). The AUCs were 0.799 (TZ) with a cutoff of 0.835 × 10mm/s, and 0.873(PZ) with a cutoff of 0.795 × 10mm/s, respectively. The total prostate-specific antigen (tPSA), free/t PSA, PSA density (PSAD), and prostate gland volume (PGV) differed significantly between patients with PI-RADS v2.1 "nodules in nodule" that were pathologically confirmed as csPCa and patients with BPH (all p < 0.05).
[CONCLUSION] In patients with PI-RADS v2.1 category 1 "nodules in nodule", when the ADC values are less than 0.835 × 10mm/s in the TZ, the PI-RADS v2.1 score of the nodule can be upgraded to 3.
MeSH Terms
Retrospective Studies; Humans; Male; Prostatic Neoplasms; Diagnosis, Differential; Diffusion Magnetic Resonance Imaging; Middle Aged; Prostatic Hyperplasia; Prostate; Aged; Aged, 80 and over
같은 제1저자의 인용 많은 논문 (5)
- Clinical outcomes and immune contexture in SMARCA4-deficient gastric cancer patients.
- Prolonged survival with alectinib in a patient with advanced lung adenocarcinoma: a case report and literature review.
- Clarifying the survival impact of immunotherapy in HR+/HER2- metastatic breast cancer: methodological caveats from a real-world perspective - Letter to the Editor.
- Magnetic resonance-guided simultaneous multi-focal adaptive radiotherapy for prostate, pElvis & metastases (MRgSMART-PEM) in prostate cancer: a prospective phase II study.
- Rethinking AI-based prediction of NAT response in breast cancer: toward mechanistic and subtype-aware modeling - Letter to the Editor.